Skip to main content
main-content

Diabetes Therapy OnlineFirst articles

12.07.2019 | Original Research Open Access

Concurrent Use of Teneligliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study

Standard treatment for type 2 diabetes mellitus consists of dietary therapy, exercise therapy and pharmacotherapy. In recent years, new drugs with different mechanisms of action have been developed for the treatment of type 2 diabetes. Dipeptidyl …

Autoren:
Tomoho Noda, Emi Ebihara, Hiroaki Ueno, Keisuke Sadohara, Yuri Tanaka, Yuuma Nagatomo, Yousuke Murakami, Shinichi Yonamine, Wakaba Tsuchimochi, Hideyuki Sakoda, Hideki Yamaguchi, Masamitsu Nakazato

10.07.2019 | Review Open Access

Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?

Understanding the implications of cardiovascular (CV) outcomes data of glucose-lowering agents on the management of type 2 diabetes mellitus can be challenging for many primary practitioners. Amongst different classes of diabetes medications …

Autoren:
Gary Deed, John J. Atherton, Michael d’Emden, Roy Rasalam, Anita Sharma, Andrew Sindone

09.07.2019 | Original Research Open Access

An Evaluation System of Fundus Photograph-Based Intelligent Diagnostic Technology for Diabetic Retinopathy and Applicability for Research

Diabetes is a common disease worldwide, with an estimated 422 million adults suffering from it as of 2014 [ 1 , 2 ]. According to the World Health Organization, this number has quadrupled since 1980 and is projected to rise rapidly [ 1 , 3 ].

Autoren:
Wei-Hua Yang, Bo Zheng, Mao-Nian Wu, Shao-Jun Zhu, Fang-Qin Fei, Ming Weng, Xian Zhang, Pei-Rong Lu

09.07.2019 | Review Open Access

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

Cardiovascular disease (CVD), including heart failure (HF), is a leading cause of morbidity and mortality in people with type 2 diabetes mellitus (T2DM). CVD and T2DM share common risk factors for development and progression, and there is …

Autoren:
Amar Ali, Steve Bain, Debbie Hicks, Phillip Newland Jones, Dipesh C. Patel, Marc Evans, Kevin Fernando, June James, Nicola Milne, Adie Viljoen, John Wilding, As part of The Improving Diabetes Steering Committee

08.07.2019 | Original Research Open Access

Successful Healthcare Provider Strategies to Overcome Psychological Insulin Resistance in Japanese Patients with Type 2 Diabetes

The global incidence of diabetes has been steadily increasing over the past few decades [ 1 ]. In Japan, the increasing prevalence of diabetes, particularly type 2 diabetes mellitus (T2D), is a major health concern [ 2 ]. Additionally, the …

Autoren:
Kentaro Okazaki, Tomotaka Shingaki, Zhihong Cai, Magaly Perez-Nieves, Lawrence Fisher

02.07.2019 | Review Open Access

Glucocrinology of Modern Sulfonylureas: Clinical Evidence and Practice-Based Opinion from an International Expert Group

Oral antidiabetics (OADs) are oral medications prescribed to patients with type 2 diabetes mellitus (T2DM). Various factors that are considered in the management of diabetes mellitus with oral medications include efficacy, safety, tolerability …

Autoren:
Sanjay Kalra, A. K. Das, M. P. Baruah, A. G. Unnikrishnan, Arundhati Dasgupta, Parag Shah, Rakesh Sahay, Rishi Shukla, Sambit Das, Mangesh Tiwaskar, G. Vijayakumar, Manoj Chawla, Fatimah Eliana, Ketut Suastika, Abbas Orabi, Aly Ahmed Abdul Rahim, Andrew Uloko, Silver Bahendeka, Abdurezak Ahmed Abdela, Fariduddin Mohammed, Faruque Pathan, Muhammed Hafizur Rahman, Faria Afsana, Shajada Selim, Muaz Moosa, Moosa Murad, Pradeep Krishna Shreshtha, Dina Shreshtha, Mimi Giri, Wiam Hussain, Ahmed Al-Ani, Kaushik Ramaiya, Surender Singh, Syed Abbas Raza, Than Than Aye, Chaminda Garusinghe, Dimuthu Muthukuda, Muditha Weerakkody, Shyaminda Kahandawa, Charlotte Bavuma, Sundeep Ruder, Koy Vanny, Manish Khanolkar, Leszek Czupryniak